BA
LAB icon

BlackRock Advisors’s Standard BioTools LAB Stock Holding History

BlackRock Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$106K Hold
14,571
– – ﹤0.01% 3016
2016
Q3 		$117K Buy
14,571
+42
+0.3% +$386 ﹤0.01% 2957
2016
Q2 		$131K Buy
14,529
+1,373
+10% +$12.9K ﹤0.01% 2820
2016
Q1 		$106K Buy
13,156
+912
+7% +$6.58K ﹤0.01% 2893
2015
Q4 		$132K Sell
12,244
-6,568
-35% -$64.5K ﹤0.01% 2797
2015
Q3 		$153K Buy
18,812
+12
+0.1% +$189 ﹤0.01% 2878
2015
Q2 		$455K Buy
18,800
+983
+6% +$31K ﹤0.01% 2257
2015
Q1 		$750K Buy
17,817
+2,219
+14% +$87.7K ﹤0.01% 1763
2014
Q4 		$526K Sell
15,598
-655
-4% -$18.5K ﹤0.01% 1964
2014
Q3 		$398K Sell
16,253
-342
-2% -$9.62K ﹤0.01% 2146
2014
Q2 		$488K Sell
16,595
-837
-5% -$26.8K ﹤0.01% 2037
2014
Q1 		$768K Buy
17,432
+558
+3% +$24.5K ﹤0.01% 1718
2013
Q4 		$646K Buy
16,874
+1,036
+7% +$30.5K ﹤0.01% 1841
2013
Q3 		$347K Buy
15,838
+786
+5% +$15.4K ﹤0.01% 2179
2013
Q2 		$263K Buy
+15,052
New +$264K ﹤0.01% 2301

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's LAB Position: Q4 2016 in Review

BlackRock Advisors held its Standard BioTools (LAB) position steady in Q4 2016 at 14,571 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #3016.

BlackRock Advisors first reported a position in LAB in Q2 2013 and has held it in 15 quarters since. The position peaked at $768K in Q1 2014. 83 funds tracked by Wall St. Rank hold LAB as of Q4 2016.

  • BlackRock Advisors held 14,571 shares of Standard BioTools worth $106K as of Q4 2016.
  • BlackRock Advisors left its Standard BioTools share count unchanged in Q4 2016.
  • Standard BioTools made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3016 holding.
  • BlackRock Advisors first reported a position in Standard BioTools in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Standard BioTools position peaked at $768K in Q1 2014.
  • 83 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.